Crinetics Pharmaceuticals (CRNX) Net Cash Flow Growth (3y) (2020 - 2026)
Crinetics Pharmaceuticals (CRNX) Net Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 32.17% |
| 10 | Crinetics Pharmaceuticals | 8.73 Bn | 7.44 Bn | 10.53 Mn | 14.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.57% |
| Dec 31, 2025 | -96.11% |
| Sep 30, 2025 | 57.00% |
| Jun 30, 2025 | 21.13% |
| Mar 31, 2025 | -45.53% |
| Dec 31, 2024 | -49.58% |
| Sep 30, 2024 | 42.22% |
| Jun 30, 2024 | -48.59% |
| Mar 31, 2024 | 201.11% |
| Dec 31, 2023 | -52.60% |
| Sep 30, 2023 | 63.88% |
| Jun 30, 2023 | -26.30% |
| Mar 31, 2023 | -6.99% |
| Dec 31, 2022 | 27.39% |
| Sep 30, 2022 | -86.20% |
| Jun 30, 2022 | -198.92% |
| Mar 31, 2022 | -71.99% |
| Dec 31, 2021 | 32.27% |
| Sep 30, 2021 | -29.47% |
| Jun 30, 2021 | 150.54% |